Libra Therapeutics is focused on developing novel disease-modifying therapeutics that can restore the cellular balance disrupted in neurodegenerative diseases. These include amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), Alzheimer's, Parkinson's, and Huntington's disease, which are all characterized by cellular disequilibrium caused by the production and decreased clearance of neurotoxic proteins. The company’s therapeutic platform is uniquely positioned to discover and develop small molecule drugs with distinct molecular approaches that can 1) increase autophagy to more rapidly clear toxic proteins and 2) attenuate the production of neurotoxic proteins.
Company Details
- Employees
- 6
- Founded
- -
- Address
- San Diego, California, Us
- in****@****ics.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- libratherapeutics.com
- HQ
- San Diego, California
Libra Therapeutics Questions
Libra Therapeutics's website is libratherapeutics.com
Libra Therapeutics's LinkedIn profile is https://www.linkedin.com/company/libra-therapeutics
Libra Therapeutics has
6 employees.
View email and phone details for 6
employees at Libra Therapeutics.
Libra Therapeutics's industry is
Biotechnology Research
Libra Therapeutics's top competitors are
Contineum Therapeutics,
Alloy Therapeutics, Inc.,
Tenvie Therapeutics,
Antios Therapeutics,
Nervgen Pharma Corp.,
Marvel Biosciences Corp.,
Deciduous Therapeutics,
Amber Ophthalmics,
Switch Therapeutics,
Nuvie Bio.
Libra Therapeutics's support email address is info@libratherapeutics.com
Libra Therapeutics's categories are Biotechnology Research
Libra Therapeutics's founding year is 2019
